BRD4 Degradation by Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL (Abstract #2050)
Our PROTAC technology represents a completely novel approach to the targeted therapy of cancer and many other diseases, and we are delighted to be working with Genentech on their targets of interest.
Genentech has one of the premier R&D organizations in the industry and I am particularly looking forward to working with them to explore fully the potential of our PROTAC protein degradation technology," commented Craig Crews, Ph.
recruit an E3 ubiquitin ligase to a specific targeted protein labeling that protein for elimination by the Ubiquitin/Proteasome System.
This is strong evidence that PROTACs could be a better and more efficacious strategy for targeting BRD4 than traditional small molecule inhibitors.
In light of the enormous potential of BRD4 degradation across a wide range of both hematologic malignancies and solid tumors, Arvinas is committed to advancing its program in order to further understand the benefit that BRD4 PROTACs could provide for patients," said Manuel Litchman, M.